Diabetes mellitus

Regulation of glucose metabolism Insulin a ins. sensitivity vs. resistance Classification of DM PP of primary types of DM – T1DM and T2DM Acute and chronic complications of DM





Definition of diabetes mellitus (DM)

- DM is a group of metabolic disorders characterized by hyperglycemia resulting from a lack of insulin effect
 - due to either defect in insulin secretion or insulin action
- chronic hyperglycemia leads to long-term cell, tissue & organ damage = diabetic complications
 - retina
 - kidney
 - nerves



Fasting vs. absorptive state






Copyright @ 2001 Benjamin Cummings, an imprint of Addison Wesley Longman, Inc.

MUNT

Regulation of glycemia




- humoral
 - principal
 - insulin
 - glucagon
 - auxiliary
 - glucocorticoids
 - adrenalin
 - growth hormone
- neural
 - sympaticus
 - hyperglycemia
 - parasympaticus
 - hypoglycemia

MUNI


What happens (in healthy man) after meal = insulin orchestrates allocation and utilisation of nutrients

diabetic "triumvirate"





What happens (in healthy man) after meal = insulin orchestrates allocation and utilisation of nutrients




liver

•

- stimulation of glycogen formation (up to~ 5% of liver weight)
 - \uparrow hexokinase, phosphophructokinase, glycogensynthase
 - \downarrow G-6-P-kinase
- inhibition of gluconeogenesis
 - ↓ PEPCK
 - fat formation
- proteosynthesis
 - ↑ transport of AA
- inhibition of ketogenesis
- muscle
 - translocation of GLUT4
 - formation of glycogen
 - proteosynthesis
- adipose tissue
 - translocation of GLUT4
 - Glc \rightarrow glycerol
 - stimulation of adipogenesis
 - ↑ activity of LPL
 - hydrolysis of VLDL and resynthesis of TAG
 - \downarrow hormone-sensitive lipase
- brain
 - insulin participates in the control of appetite/satiety

Diagnosis of DM


- diabetes
 - classical symptoms + random plasma glycemia
 ≥11.1 mmol/l (venous plasma)
 - random = any time of the day
 - symptoms include polyuria and polydipsia
 - FPG (fasting plasma glucose) ≥7.0 mmol/l
 - fasting means at least 8 h from the last meal
 - 2-h PG (postprandial glucose) ≥11.1 mmol/l during oGTT
 - oGTT: according to the WHO consists of FPG examination followed by a standard load of 75g of glucose (diluted in water) and examination of glycemia in 60th and 120th minute
- impaired glucose tolerance (IGT)
 - excluded <7.8 mmol/l
 - 2-h PG ≥7.8 <11.1 mmol/l during oGTT
- impaired fasting glucose (IFG)
 - diabetes excluded by FPG ≤5.6 mmol/l
 - FPG ≥5.6 <7 mmol/l




 $M \in D$




Importance of fasting plasma glucose measurement




Q1: The way glucose enters the cell??









INSULIN SECRETION VS. INSULIN SENSITIVITY / RESISTANCE

MUNI Med

Insulin – world diabetes day

- 14/11 (od 1991)
- birthday of the man who co-discovered insulin, Frederick Banting
- Banting discovered insulin in 1922 alongside Charles Best under the directorship of John McLeod and with assistance of James Collip
- The Nobel Prize in Physiology or Medicine 1923 was awarded jointly to Frederick Grant Banting and John James Rickard Macleod "for the discovery of insulin"







MUNI

Insulin


- exocytosis from B-cells of islets of Langerhans into portal circulation
 - 50% degraded during first pass through liver
 - parallel cleavage of the C-peptide
- total daily production in healthy subject ~20-40 U
 - 1/2 basal (postabsortive) secretion
 - pulsatile (5 15 min intervals)
 - 1/2 stimulated (postprandial)
 - early phase (ready insulin)
 - Glc/K_{ATP}-dependent
 - late phase (synthesis de novo)
 - other secretagogues
- stimulation of secretion
 - < << glucose
 - <<amino acids
 - <GIT hormones (incretins)
 - FFA
 - variable stimulation (length of chain & (un)saturation)!!
 - since insulin is acting also as peripheral "satiety" signal, reaching the satiety is delayed after fatty meal





MUNT

Insulin synthesis





MUNI Med


Langerhans islets - architecture

Delta cel!

- The pancreatic islet blood flow is 5–10 times higher than that of the exocrine pancreas, and can be selectively enhanced whenever the need for insulin secretion is increased
- B-A-D flow hypothesis
 - that is why contra-regulation insulin/glucagon works so well









C peptide


- activity
 - certain beneficial vascular effects (nitric oxide)
- mainly diagnostic use
 - equimolar to insulin
 - unlike insulin, C-peptide is not degraded from portal blood in liver
 - the systemic concentration reflects endogenous insulin production



A U N T




Coupling: glycemia – insulin secretion




MUNI Med

Hexokinase vs. glucokinase



- hexokinase (ubiquitously with exception of liver and pancreatic b-cells)
 - activity increases with increased glucose but activity is inhibited by increased G6P
 - levels of enzyme are constitutive
 - only generates ATP when energy is required
 - glucokinase (hepatocytes and b-cells)
 - is not normally active because its Km is lower than normal blood glucose levels
 - eating food increases glu in blood, activates glucokinase which converts glu to glycogen and fatty acids
 - activity increases with increased glucose but is not inhibited by increased glu6PO4
 - the levels of the protein are regulated by insulin
 - rate of reaction is driven by substrate-glucose not by demand for product-G6P
 - allows all glu available to be converted to G6P and then if excess present, it is converted to glycogen and from there to triglycerides and fatty acids


 $M \vdash D$



MUNI Med

NEFA and insulin secretion


- NEFA can enter cells (incl. B-cells)
 - directly by diffusion across the membrane (short-chain FA) \rightarrow metabolism (oxidation) \rightarrow ATP insulin secretion
 - via receptor (GPR40) \rightarrow see the figure
- however, long term exposure to NEFA, esp. long-chain saturated (e.g. palmitate), suppress secretion of insulin and damages B-cells



 $M \vdash D$

Incretins – enteroinsular axis

- GIT hormones produced by endocrine cells of small intestine stimulating insulin secretion even before elevation of blood glucose
 - Ins-secretion after oral Glc >> after i.v. Glc
 - hypoglycemia if the patient still conscious then better to give Glc per os
- "forward" regulatory mechanism anticipation of increase of Glc
- 2 major incretin hormones
 - GIP (glucose-dependent insulinotropic peptide or gastric inhibitory peptide)
 - GLP-1 (glucagon-like peptide-1)
- treatment of T2DM [= delayed effect of Glc on Ins stimulation] by incretin analogues
 - GLP-1 analogue exenatide (GLP-receptor agonist)
 - DPP-4 inhibitors (dipeptyl peptidase 4 proteolytic degradation of incretins) gliptins
 - improvement of Glc-stimulated Ins secretion after meal
 - supression of postprandial glucagon release
 - delayed gastric emptying
 - protection of β-cells from apoptosis






 $M \vdash D$


Gila monster



MUNI

Effect of GLP-1 – anticipation of need to rise insulin









Jens Juul Holst Physiol Rev 2007;87:1409-1439 Physiological Reviews

Incretins have systemic effects too




MUNI Med



INSULIN SIGNALLING




Insulin receptor



MUNI Med

Insulin receptor made simple



- insulin receptor is a **tyrosinkinase** type (2 α and 2 β subunits) receptor
- signal transduction consists of series of phosphorylation events
 - intracellular proteins, other kinases and finaly enzymes
 - i.e. their activation or inhibition
 - activation of anabolic pathways (i.e. glycegenogenesis, lipogenesis)
 - inhibition of catabolic pathways (e.g. lipolysis, glycogenolysis) and gluconeogenesis
- two main effects happen in insulin-dependent tissues
 - (1) ↑ glucose uptake
 - by translocation of GLUT4 in sceleatl muscle and adipose tissue
 - (2) metabolic: IRS \rightarrow PI-3-K \rightarrow PDK \rightarrow PKB (=Akt)
 - \rightarrow GSK (glycogen-synthase-kinase) \rightarrow \uparrow glycogen synthesis
 - \rightarrow cAMP phosphodiesterase \rightarrow inhibition of lipolysis


 $M \vdash D$

- \downarrow gluconeogenesis
- ubiquitously (3) ↑ gen. expression (mitogenic effect)
 - MAPK \rightarrow transcription factors

Classification of tissues according to insulin action:

• insulin-dependent

- skeletal and heart muscle
- adipose tissue
 - in both glucose uptake facilitated by GLUT4, which becomes integrated into cell membrane after insulin receptor activation




- liver
 - metabolic actions

- insulin-independent
 - all others
 - glucose uptake is realized by facilitated diffusion by GLUT1, 2, 3, 5, ... permanently localized in the cell membrane
 - transport of glucose depends solely on
 - concentration gradient
 - type and density of GLUTs
 - NOTE skeletal and heart muscle, adipose and liver also express insulinindependent GLUTs

 $M \vdash D$

Insulin sensitivity – a hyperbolic relation between i. secretion and sensitivity




- Insulin sensitivity refers to the body's ability to dispose of glucose
 - x-axis represents the amount of glucose cleared at a given insulin dose
- A variety of evidence has shown that active individuals clear greater glucose with lower insulin secretion than sedentary individuals
 - that is, active individuals are more insulin sensitive
 - becoming inactive and or obese makes you insulin resistant
- As sedentary individuals become progressively more insulin resistant, pancreatic beta cells hypertrophy and eventually become unable to secrete sufficient insulin to clear glucose from the blood after a meal

 $M \in D$

• This end state is referred to as glucose intolerance

Insulin sensitivity assessment

- insulin sensitivity (= given effect of dose of insulin on individual's glycaemia) is a continuous trait
- distinct interindividual variability
- it can be assessed by:
 - hyperinsulinemic euglycemic clamp
 - calculated indexes (based on relationship between glycaemia and insulin during fasting or oGTT)
 - e.g. HOMA, QUICKI, ...
- insulin sensitivity changes (= insulin resistance) in many situations
 - physiologically in pregnancy
 - pathologically in obesity, inflammation etc.
- should increasing insulin resistance always lead to compensatory increase of insulin secretion than glycaemia would stay stable
 - however capacity to compensatory increase secretion of insulin by beta-cells is apparently limited



 $M \vdash D$



CLASSIFICATION OF DM, T1DM A T2DM



Pathophysiology of diabetes mellitus


- heterogeneous syndrome characterized by hyperglycemia due to deficiency of insulin action as a result of
 - absolute insulin deficiency
 - destruction of the β -cells of the islets of Langerhans
 - relative deficiency of insulin secretion and/or action
 - abnormal molecule of insulin (mutation of insulin gene)
 - defective conversion of preproinsulin to insulin
 - circulating antibodies against insulin or its receptor
 - insulin resistance in peripheral tissues + secondary failure of β -cells of the islets of Langerhans

 $M \vdash U$

- receptor defect
- post-receptor defect
- prevalence of DM in general population 5%, over the age of 65 already 25%

Prevalence (%) of diabetes (population 20-79 years)

2010 – 4.3 bil. (from a total of 7 bil.)
285 mil. diabetics
0.75 mil. diabetics in Czech rep.



[IDF Diabetes Atlas, 4th ed. ©International Diabetes Federation, 2009]

438 mil. diabetics

2030 – 5.6 bil. (from a total of 8.5 bil.)

1.2 mil. diabetics in Czech Rep.

30%

54%

60%

 $M \cup N \top$

Classification of DM

- Diabetes mellitus type 1 (T1DM) ~5%
- Diabetes mellitus type 2 (T2DM) ~90%
- Gestational diabetes mellitus (GDM) ~10 15% of pregnant women
- Monogenic DM ~2%
 - neonatal
 - MODY (1 6)
- Secondary
 - diseases of exocrine pancreas
 - chron. pancreatitis, tumor, cystic fibrosis, hemochromatosis
 - endocrine disorders (insulin contra regulation)
 - Cushing syndrome, acromegaly, pheochromocytoma, hyperthyreosis
- **Drug induced** (iatrogenic) DM
 - glucocorticoids and others
- Other forms (syndromic)
 - mutation of mitochondrial DNA
 - genetic defects leading to insulin resistance (type A insulin resistance, leprechaunismus, Rabson-Mendenhal syndrome, lipoatrophic DM)
 - other genetic syndromes associated with DM (m. Down, Klinefelter, Turner)

Classification of DM

1. Diabetes mellitus type 1 (T1DM) ~5%

2. Diabetes mellitus type 2 (T2DM) ~90%

3. Other specific types:

- a. genetic defects of B-cell
 - monogenic DM (MODY1 6)
 - mutation of mitochondrial DNA
- b. genetic defects leading to insulin resistance
 - type A insulin resistance, leprechaunismus, Rabson-Mendenhal syndrome, lipoatrophic DM
- c. diseases of exocrine pancreas
 - pancreatitis, tumor, cystic fibrosis, hemochromatosis
- d. endokrinopathies
 - Cushing syndrome, acromegaly, pheochromocytoma, hyperthyreosis
- e. iatrogenic DM (i.e. drugs and toxins)
- f. other genetic syndromes associated with DM
 - Down, Klinefelter, Turner syndromes, ...

4. Gestational diabetes mellitus








From insulin resistance to T2DM


- insulin sensitivity changes (= insulin resistance) in many situations
 - physiologically in pregnancy
 - pathologically in obesity, inflammation etc.
- should increasing insulin resistance always lead to compensatory increase of insulin secretion than glycaemia would stay stable
 - however capacity to compensatory increase secretion of insulin by beta-cells is apparently limited
- main pathophysiologic feature of T2DM is an imbalance between insulin secretion and its effect
 - in the time of clinical manifestation there are both insulin resistance and impairment of insulin secretion
- what is "chicken" and what is "egg"??
 - see later T2DM genetics




 $M \vdash I$

What determines insulin resistance and/or insulin secretion?

- insulin resistance
 - genetic predisposition (polygenic) thrifty genotype/phenotype
 - acquired factors
 - diet high fat/low fiber
 - competition of GIs with NEFA!!!
 - obesity 90% T2DM are obese
 - effect of adipokines from adipose tissue (visceral!)
 - low-grade inflammation
 - lipid spillover competition with Glc
 - several other mechaisms
 - physical inactivity \downarrow mobilization of GLUT4
 - down-regulation of ins. receptor due to hyperinsulinemia
- impairment of insulin secretion
 - inherited factors genetics
 - fewer B-cells (~20-40%)
 - defect of 1. phase of Ins secretion (~80% reduction)
 - acquired factors
 - gluco- and lipotoxicity for B-cells




Metabolic syndrome – a unifying effect of obesity




Genetics of T2DM

Grouped T2DM susceptibility loci



 Genome-wide association studies (GWAS) have identified over 400 genetic signals that are associated with altered risk of T2DM. Human physiology and epigenomic data support a central role for the pancreatic islet in the pathogenesis of T2DM


Genetics of T2DM – a spectrum of impairments




Predominantly insulin resistant monogenic T2DM Mutations in insulin receptor, PPARy, AKT-2 genes

 $M \cup N \top$

Natural history of T2DM – time course





Natural history of T2DM – disease mechanisms



progression (years)

Insulin- and "sport"-dependent translocation of GLUT4






- 2 intracellular "pools" of GLUT4
 - insulin-dependent (see cascade of Ins-receptor)
 - Ca^{2+ /} NO / AMPK?-dependent
 - this mechanism is responsible for improvement of insulin sensitivity in physically active subjects

²Secondary failure of β cells


- hyperglycemia induces:
 - oxidative stress
 - endoplasmic reticulum (ER) stress
- high concentration of NEFA causes lipotoxicity
 - short term increase of NEFA stimulates secretion of insulin
 - long term exposure to NEFA, esp. long-chain saturated (e.g. palmitate), suppress secretion of insulin and damages B-cells
 - \uparrow ceramide \rightarrow **apoptosis**




 $M \vdash I$

ER stress \rightarrow **Unfolded protein response**

- The unfolded protein response (UPR) is activated in response to an accumulation of unfolded or misfolded proteins in the lumen of ER
 - incl. insulin in β -cells
- UPR has two primary aims:
 - initially to restore normal function of the cell by halting protein translation and activate the signaling pathways that lead to increasing the production of molecular chaperones involved in protein folding
 - if these objectives are not achieved within a certain time lapse or the disruption is prolonged, the UPR aims to apoptosis



Overt T2DM




 $M \vdash I$

- manifest T2DM is characterized by (variable degree of):
 - fasting hyperglycemia (due to gluconeogenesis)
 - insulin resistance in liver
 - postprandial hyperglycemia (due to decreased peripheral glucose uptake
 - insulin resistance in muscle and adipose tissue
 - mixed dyslipidemia
 - increased plasma NEFA (due to unsuppressed lipolysis)
 - insulin resistance in adipose tissue
 - pro-atherogenic dyslipidemia (due to stimulated VLDL production in liver)
 - substrate effect

Gestational diabetes mellitus (GDM)

- GDM develops during pregnancy (gestation) and it is one of the most common health problems of pregnancy
 - up to 10% of expectant mothers
- GDM is a serious problem because high blood sugar affect both mother and offspring
- GDM pathophysiology
 - hormonal changes in physiological pregnancy (i.e. placental hormones) cause mild insulin resistance
 - this is beneficial for the foetus and baby since glucose is the nutrient and insulin a growth hormone
 - placenta is ready and glucose-screening test is thus performed typically between 24 and 28 weeks
 - this requires additional insulin and normal pancreas can keep up with increased demands
 - if not, blood glucose levels rise too high, resulting in GDM
 - risk factors: age, overweight/obesity, susceptibility genes for T2DM, diet
- maternal hyperglycaemia stimulates baby's pancreas to produce more insulin to process the extra glucose
 - as a result baby can put on extra weight (macrosomia) with subsequent complications during the birth (shoulder dystocia, fractured bone or nerve damage)
 - hence the recommendation for early caesarean section
 - additionally, foetal hyperinsulinemia increases the risk of **post-delivery hypoglycaemia**
 - babies who have excessive fat stores as a result of high maternal sugar levels during pregnancy often continue to be overweight in childhood and adulthood (foetal programming)
- blood sugar usually returns to normal soon after delivery, however, GDM increases the risk for getting it again during the future pregnancy and for developing diabetes (T2DM) later in life (up to 50% post-GDM subjects!!!)



 $M \vdash I$

Other than type 1 and 2 forms of DM

- LADA (Latent Autoimmune Diabetes in Adults) = slow-onset T1DM
 - diagnosis in > 30yrs of age, clinically similar to T2DM (slow onset)
 - initially on diet and pills, no ketoacidosis
 - later insulin dependent (during months 1 year)
 - positive antibodies (= autoimmunity), low or no C-peptide
 - negative family history of T2DM
- MODY (Maturity-onset diabetes of the young) cca 5% T2DM
 - monogenic diabetes with familiar clustering and well defined (Mendelian) inheritance (usually AD), early manifestation (childhood or adolescence) and without obesity
 - 6 types (MODY1-6)
 - pathophysiology: genetically conditioned **dysfunction of** β-cells but long-term measurable C-peptide without the signs of autoimmunity
 - MODY due to glucokinase mutations (MODY2)
 - glucokinase = "glucose sensor" (impaired insulin secretion)
 - milder form without the complication risk
 - MODY due to transcription factor mutations (other 5 types)
 - severe defects of β -cells progressively leading to diabetes with complications
 - impairment of glucose-stimulated insulin secretion and proliferation and differentiation of β -cells

MODY	lokus	gen	produkt	prim. defekt	závaž	,
1	2 0 Q	HNF4A	hepatocyte nuclear factor-4 α	pankreas	vysoká	časté
2	7 р	GCK	glukokináza	pancreas/játra	mírná	vzácně
3	ક ટ હ	TCF1 (HNF1A)	hepatocyte nuclear factor-1 $lpha$	pancreas/ledviny	vysoká	časté
4	ક ૩ હ	IPF1	insulin promoter factor-1	pancreas	vysoká	?
5	17q	TCF2 (HNF4B)	hepatocyte nuclear factor-1 eta	pancreas/ledviny	vysoká	renální
6	2q32	NEUROD1	NEUROD1	pankreas	vysoká	?








T1DM (formerly IDDM)


- selective autoimmune destruction of β cells of lofL in genetically predisposed individuals
- genetic susceptibility
 - chromosome 6 MHC class III
 - DR3-DQ2 and DR4-DQ8
 - chromosome 11 insulin gene
 - promotor polymorphism (variable length)
 - in both cases genetic background leads to insufficient deletion of autoreactive T-lymphocytes in thymus and therefore **suboptimal central immune (auto)tolerance**
- cytotoxic autoimmunity mediated by Tlymphocytes
 - there are also antibodies against β cell structures (ICA, GAD, IAA), but they are rather markers of autoimmunity than causal agents
- common association of T1DM with other autoimmune diseases
 - celiac disease
 - thyreopathy,
 - Addison syndrome



 $M \vdash D$

T1DM

- autoimmunity has to be triggered by various factors
 - infection
 - viruses
 - rubella, measles, coxsackie B, CMV, EBV, enteroviruses, retro-viruses
 - mechanism is unclear
 - cytolytic (
 sequestration of antigens
 - formation of neoantigens
 - molecular mimicry or superantigens
 - environmental factors (according to the epidemiologic evidence)
 - diet early exposition proteins of cow's milk
 - bovine insulin
 - vitamin D reason for northernsouthern geographical gradient?
 - toxins (diet, water, bacteria)
 - gluten???
- manifestation typically in childhood
- absolute dependence on exogenous supplementation by insulin



time (months to years)



A U N T

 $M \in D$



b Early twenty-first century Number of cases Number of cases 50 50 100 100 0 0 Degree of genetic or environmental contribution to T1DM (%) Degree of genetic or environmental contribution to T1DM (%) Genetic factors Environmental factors

a Early twentieth century

MUNI MED

Insulin treatment historically




2 tuny prasečích slinivek \Rightarrow cca 100g inzulinu









Insulin treatment nowadays (analogues)



Insulin treatment nowadays (analogues)





MUNI





Main characteristics – comparison - of T1DM and T2DM





	T1DM	T2DM
onset	childhood	adults
genetic disposition	yes (oligogenic)	yes (polygenic)
clinical manifestation	often acute	mild or none
autoimmunity	yes	No
insulin resistance	no	yes
dependence on insulin	yes	No
obesity	no	yes

Acute manifestation and long-term consequences (complications) of diabetes



Q2: Effect of rising plasma glucose ???

OSMOLARITA = 2 Na^+ + urea + glukóza

 $275 - 295 = 2 \times 140 + 2.5 + 5$

> 300 = 2 x 140 + 2.5 + **35**

 $M \in D$

Clinical presentation of DM

- due to the mild increase of blood
 osmolarity, osmotic diuresis and dehydratation
 - classical
 - polyuria, thirst, polydipsia
 - tiredness
 - temporary impairment of vision
 - others
 - recurrent infections
 - perio-/parodontitis


extreme hyperglycemia (>40 mmol/l,
osmolarity >350 mosmol/l)

- ketoacidosis/coma
 - ↑ ketone bodies, metabolic acidosis an d hyperglycemia
- non-ketoticidotic hyperglycemic coma
 - hyperglycemia, dehydration and pre-renal uremia
- lactic acidosis/coma
 - either complication of therapy (biguanides / type of peroral antidiabetics)
 - associated with hypoxic states (sepsis, shock, heart failure, ...)


 $M \vdash I$

Diabetic ketoacidosis

- Excessive thirst
- Frequent urination
- Nausea and vomiting
- Abdominal pain
- Weakness or fatigue
- Shortness of breath
- Fruity-scented breath
- Confusion







UNT

Late complications of DM


- microvascular
 - diabetic retinopathy
 - diabetic nephropathy
 - diabetic kidney disease (DKD)
 - diabetic neuropathy
 - sensoric
 - motoric
 - autonomous

- macrovascular
 - accelerated atherosclerosis (CAD, peripheral and cerebrovascular vascular disease)
- combined
 - diabetic foot (ulcerations, amputations and Charcot's joint)


 $M \vdash D$

- others
 - periodontitis
 - cataract
 - glaucoma

Chronic hyperglycemia




Pathogenesis of complications



MUNT

Advanced glycation end products (AGEs)



Maillard reaction in food – AGEs in diet



- AGEs are similar to products of Maillard reaction (MRP) formed during thermal processing of food
 - sugar + protein
- Louis Camille Maillard (1878 1936)
 - original description of reactions during cooking ("browning") leading to formation of MRPs (=AGEs)

•MRP influence taste and visual characteristics, smell, shelve life

• biologic properties of MRP

positive – antioxidants

 melanoidins, polyphenols

 negative – carcinogens

 acrylamid



MUNT





Kinetics of AGEs in organism

